Ascendis Pharma A/S vs Omnicom Group Inc. — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.67B), while Omnicom Group Inc. trades at $85.74 (market cap $23.58B). The key difference: Omnicom Group Inc. is the larger of the two by market cap, and Omnicom Group Inc. pays a 3.72% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | OMC | |
|---|---|---|
Market Cap | $16.67B | $23.58B |
Sector | Health | Media |
52-Week High | $277.18 | $86.22 |
52-Week Low | $189.74 | $67.27 |
Enterprise Value | $17.04B | $31.66B |
Dividend Yield | — | 3.72% |
Trailing returns across standard periods
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →